



(51) International Patent Classification:

A61K 31/519 (2006.01) *A61K 45/06* (2006.01)
A61K 31/5377 (2006.01) *A61P 35/00* (2006.01)
A61K 31/553 (2006.01)

(21) International Application Number:

PCT/EP2024/059956

(22) International Filing Date:

12 April 2024 (12.04.2024)

(25) **Filing Language:** English

(26) **Publication Language:** English

(30) Priority Data:

63/496,040 14 April 2023 (14.04.2023) US

(71) **Applicant: ASTRAZENECA AB** [SE/SE]; SE-151 85 Södertälje (SE).

(72) **Inventors:** **KOERS, Alexander**; ASTRAZENECA UK LIMITED, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge Cambridgeshire CB2 0AA (GB). **LAU, Alan**; ASTRAZENECA UK LIMITED, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge Cambridgeshire CB2 0AA (GB). **ROSS, Sarah**; ASTRAZENECA UK LIMITED, 1 Francis Crick Avenue,

Cambridge Biomedical Campus, Cambridge Cambridgeshire
CB2 0AA (GB).


(74) **Agent: ASTRAZENECA INTELLECTUAL PROPERT**
TY; Eastbrook House, Shaftesbury Road, Cambridge Cam-
 bridgeshire CB2 8BF (GB).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: COMBINATIONS OF KRAS INHIBITOR AND ATR INHIBITOR FOR THE TREATMENT OF CANCER

FIG. 1



(57) Abstract: The present provides a method of treating cancer in a subject, the method comprising administering to the subject: (a) a KRAS inhibitor, and (b) an Ataxia Telangiectasia and Rad-3-related (ATR) inhibitor. Also disclosed are compositions and kits comprising (a) a KRAS inhibitor, and (b) an ATR inhibitor.

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*